HER2 Support Group Forums - View Single Post

Lani · 05-28-2009, 07:37 AM

Brain metastases are prevalent in triple negative and HER2-
overexpressing (HER2+) subpopulations, and the incidence of brain
metastases approaches one-third of all metastatic HER2+ patients.
HER2+ status was found to specifically increase brain colonization
2.5-fold to 3-fold, although not affecting tumor cell arrival or intra-
vasation into the brain.

Excitingly, a study of 14C-lapatinib distribu-
tion in a 231-BR xenograft model showed a significant increase of its
distribution to the metastasis over normal brain. Indeed, lapatinib
inhibited the formati on of clinical metastases in HER2/EGFR-
expressing 231-BR cells by 54%, suggesting activity in the adjuvant
setting (2). Current work is examining rational combinations to
elicit synergistic effects with radiation and other targeted agents.

Could we ever get lapatinib cheap enough to be a preventive agent against brain mets adjuvantly?

05-28-2009, 07:37 AM	#1
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	the bad and the good Brain metastases are prevalent in triple negative and HER2- overexpressing (HER2+) subpopulations, and the incidence of brain metastases approaches one-third of all metastatic HER2+ patients. HER2+ status was found to specifically increase brain colonization 2.5-fold to 3-fold, although not affecting tumor cell arrival or intra- vasation into the brain. Excitingly, a study of 14C-lapatinib distribu- tion in a 231-BR xenograft model showed a significant increase of its distribution to the metastasis over normal brain. Indeed, lapatinib inhibited the formati on of clinical metastases in HER2/EGFR- expressing 231-BR cells by 54%, suggesting activity in the adjuvant setting (2). Current work is examining rational combinations to elicit synergistic effects with radiation and other targeted agents. Could we ever get lapatinib cheap enough to be a preventive agent against brain mets adjuvantly?